m6A modulators also reduce or exacerbate resistance to chemoradiotherapy in cancer patients.168 For example, targeting SNHG3/miR-186-5p reversed platinum treatment-induced elevated m6A levels by modulating METTL3 in esophageal cancer.529 m6A modification of FZD10 mRNA leads to PARPi resistance in BRCA-deficient epithelial ovarian cancer cells by upregulating the Wnt/β-catenin pathway.530 In addition, METTL3 can promote chemoresistance and radioresistance of pancreatic cancer cells.531 In terms of immunotherapy, two studies also revealed that m6A might be related to cancer immunotherapy. The gene discussed is METTL3; the disease is ovarian carcinoma.